{"filing":{"accession_number":"0001171843-26-004112","cik":"0001729214","ticker":"XRTX","company_name":"XORTX Therapeutics Inc.","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"f6k_061526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1729214/000117184326004112/f6k_061526.htm"},"events":[{"id":12226,"run_id":10790,"accession_number":"0001171843-26-004112","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The press release's primary disclosure is the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets. The release states \"Ongoing evaluation of our corporate team and issuer status has provided the opportunity to further enhance our c-suite effectiveness and to optimize our public markets efficiency with the addition of Mika Grasso as co-CEO.\" This is a material executive appointment affecting the registrant's leadership structure and governance, with detailed biographical information provided. While the release also discusses corporate strategy and drug development programs, the headline and substantive focus is the executive appointment.","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9026,"accession_number":"0001171843-26-004112","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The press release's primary disclosure is the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets. The release states \"Ongoing evaluation of our corporate team and issuer status has provided the opportunity to further enhance our c-suite effectiveness and to optimize our public markets efficiency with the addition of Mika Grasso as co-CEO.\" This is a material executive appointment affecting the registrant's leadership structure and governance, with detailed biographical information provided. While the release also discusses corporate strategy and drug development programs, the headline and substantive focus is the executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:25:59.038059+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9026,"accession_number":"0001171843-26-004112","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The press release's primary disclosure is the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets. The release states \"Ongoing evaluation of our corporate team and issuer status has provided the opportunity to further enhance our c-suite effectiveness and to optimize our public markets efficiency with the addition of Mika Grasso as co-CEO.\" This is a material executive appointment affecting the registrant's leadership structure and governance, with detailed biographical information provided. While the release also discusses corporate strategy and drug development programs, the headline and substantive focus is the executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:25:59.038059+00:00","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-06-15"}]}